Literature DB >> 21999131

Current surgical treatment of non-small-cell lung cancer.

Paul E Van Schil1, Jeroen M Hendriks, Marjan Hertoghs, Patrick Lauwers, Cliff Choong.   

Abstract

When considering surgical treatment for non-small-cell lung cancer (NSCLC), a distinction is made between early-stage disease (stages IA/B and IIA/B), locoregionally advanced disease (stages IIIA/B) and metastatic disease (stage IV). Complete surgical resection of NSCLC can provide good long-term outcome. Surgery is considered the treatment of choice in patients with early-stage NSCLC or patients with T3N1 disease. Surgery for locoregionally advanced disease remains controversial. In specific cases of T4 disease, surgery can provide long-term survival. In patients with stage IIIA-N2 disease, surgery is only offered to patients who have achieved mediastinal downstaging following induction therapy. Careful preoperative evaluation is clearly important in the staging and selection of patients with NSCLC for surgery.

Entities:  

Mesh:

Year:  2011        PMID: 21999131     DOI: 10.1586/era.11.142

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

1.  Analysis for the mechanism between the small cell lung cancer and non-small cell lung cancer combing the miRNA and mRNA expression profiles.

Authors:  Weisan Zhang; Qiang Zhang; Mingpeng Zhang; Yun Zhang; Fengtan Li; Ping Lei
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

2.  Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non-small cell lung cancer patients.

Authors:  Yunseon Choi; Ik Jae Lee; Chang Young Lee; Jae Ho Cho; Won Hoon Choi; Hong In Yoon; Yun-Han Lee; Chang Geol Lee; Ki Chang Keum; Kyung Young Chung; Seok Jin Haam; Hyo Chae Paik; Kang Kyoo Lee; Sun Rock Moon; Jong-Young Lee; Kyung-Ran Park; Young Suk Kim
Journal:  Radiat Oncol J       Date:  2015-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.